The cohort study for live-style associated liver disease
Not Applicable
- Conditions
- Fatty Liver
- Registration Number
- JPRN-UMIN000035127
- Lead Sponsor
- Kyoto Prefectural University of Medicine Graduate School of Medical Science
- Brief Summary
SM was associated with changes in UAE (r<0.27,p<0.005). Multiple regression analysis demonstrated that LSM was associated with change in UAE (b=0.28,p<0.015) after adjusting for co-variate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 246
Inclusion Criteria
Not provided
Exclusion Criteria
Refusal or lacks capacity to give informed consent to participate in the trial.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) determined by FibroScan (Echosens, Paris, France).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link liver stiffness measurement (LSM) to urinary albumin excretion (UAE) in lifestyle-associated fatty liver?
How do lifestyle interventions compare to standard-of-care treatments like pioglitazone in reducing fibrosis in non-alcoholic fatty liver disease (NAFLD)?
Which non-invasive biomarkers predict response to lifestyle modifications in patients with non-alcoholic steatohepatitis (NASH)?
What are the potential adverse effects of long-term lifestyle changes on liver function in JPRN-UMIN000035127 participants?
How do combination therapies involving exercise and pharmacological agents like GLP-1 receptor agonists impact liver stiffness in NAFLD?